Boston Scientific (BSX) said Wednesday it has agreed to acquire the shares of Bolt Medical that it does not already own for $443 million in addition to milestone payments.

Boston Scientific said it developed the concept for Bolt's laser-based intravascular lithotripsy platform for the treatment of heart disease and already holds a 26% stake in the company.

Under the terms of the deal, Boston Scientific will acquire the remaining 74% stake in Bolt Medical for the upfront payment and up to $221 million in regulatory milestone payments.

Boston Scientific said it expects the acquisition to close in H1. It said it expects the transaction to be "slightly dilutive" to adjusted earnings per share in 2025.

Shares of the medical technology company were 2% higher in premarket trading.